Clinical trials: Chronic Obstructive Pulmonary Disease
Study Focus: 30-day Rehospitalizations Among At-risk Older Adults Randomized to a Social Work-driven Care Transitions Intervention, Heart Disease
Social Work Intervention Focused on Transitions
In response to Program Announcement (PA)-09-164, "NIH Exploratory/Developmental Research Grant Program (R21) a randomized pilot study testing the efficacy of SWIFT: Social Work Intervention Focused on Transitions among at-risk…
- Conditions
- Study Focus: 30-day Rehospitalizations Among At-risk Older Adults Randomized to a Social Work-driven Care Transitions Intervention, Heart Disease, Diabetes, Hypertension
- Trial name
- SWIFT (NCT02232126)
- Testing
- SWIFT home intervention
- Where
- 2 sites in United States
- Volunteers
- 181 people, healthy volunteers welcome
- Sponsor
- University of Southern California
COPD, Emphysema
The Effect of Physical Activity Promotion on Short and Long-term Outcomes in COPD
COPD currently afflicts 24 million US residents; the prevalence of COPD is high among Veterans. Persons with COPD have significant functional disability as a result of the disease.
- Conditions
- COPD, Emphysema, Chronic Bronchitis
- Trial name
- WEB (NCT02099799)
- Testing
- Pedometer and Website
- Where
- 2 sites in United States
- Volunteers
- 153 people
- Sponsor
- VA Office of Research and Development
Asthma
Modulation Of Airway Reactivity With Chronic Mechanical Strain
The purpose of this study is to see if the use of a machine called CPAP will help children with asthma breathe better. CPAP is a machine that produces airflow to help people with breathing problems.
- Trial name
- NCT02396849
- Testing
- Continuous Positive Airway Pressure (CPAP)
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Indiana University
Healthy
A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral Drugs
The study purpose is to evaluate the potential for a pharmacokinetic drug-drug interaction, safety and tolerability when Narlaprevir, Ritonavir (used as a metabolic inhibitor) and Tenofovir disoproxil fumarate (part 1) and…
- Trial name
- NCT03537404
- Testing
- Narlaprevir, Ritonavir, Tenofovir Disoproxil Fumarate
- Where
- Russia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- R-Pharm
Chronic Obstructive Pulmonary Disease
Efficacy and Safety Study of QVA149 in COPD Patients
The purpose of this study is to demonstrate that the efficacy of the combination product QVA149 is similar to the efficacy of the combination product umeclidinium/vilanterol on a pre-specified endpoint of FEV1 AUC0-24h while…
- Trial name
- NCT02487446
- Testing
- QVA149, Umeclidinium/vilanterol
- Where
- 58 sites in United States
- Volunteers
- 357 people
- Sponsor
- Novartis Pharmaceuticals
COPD, Sepsis
Effect of Nebulized Bronchodilators on Heart Rate
The purpose of the study is to determine adverse events rates of nebulized albuterol versus levalbuterol among adult critically ill patients and determine if a differential exists in adverse events between the two drugs.
- Conditions
- COPD, Sepsis, Shock
- Trial name
- NCT01151579
- Testing
- Levalbuterol, Albuterol
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Fahim Khorfan, MD
Respiratory Tract Diseases, Abnormal Mucus Secretions
A Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily, Ambroxol Hydrochloride 30 mg Twice Daily and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus Secretions
This is a phase 3, multicenter, randomized, rater- and patient-blind, placebo- and active-controlled, 3-arm parallel group clinical trial.
- Trial name
- NCT03843541
- Testing
- N-acetylcysteine (NAC) 600 mg, Ambroxol hydrochloride 30 mg
- Where
- 32 sites in China
- Volunteers
- 333 people
- Sponsor
- Zambon SpA
Dyspnea
Aerosol Inhalation Treatment for Dyspnea - Patients
The purpose of this protocol is to develop and test aerosol furosemide, as a treatment that has the potential to significantly improve symptom management and enhance the quality of care for patients with intractable dyspnea.
- Trial name
- NCT02524054
- Testing
- Furosemide, Aerosolized saline
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Beth Israel Deaconess Medical Center
COPD
A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD
Study for subjects 40 to 65 years-old with a diagnosis of moderate to severe COPD. Aclidinium bromide 400 mcg 2x a day will be given as an active comparator.
- Trial name
- GOLDEN 6 (NCT02038829)
- Testing
- SUN101 3 mcg, SUN-101 6.25 mcg, SUN-101 12.5 mcg
- Where
- 10 sites in United States
- Volunteers
- 96 people
- Sponsor
- Sunovion Respiratory Development Inc.
Atelectasis, Pulmonary Infection
Bi-PAP vs Sham Bi-PAP on Pulmonary Function in Morbidly Obese Patients After Bariatric Surgery
The effect of biphasic positive airway pressure (Bi-PAP) at individualized pressures on the postoperative pulmonary recovery of morbidly obese patients (MOP) undergoing open bariatric surgery (OBS) and possible placebo…
- Conditions
- Atelectasis, Pulmonary Infection, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Disease
- Trial name
- NCT03438383
- Testing
- Bi-PAP
- Volunteers
- 48 people
- Sponsor
- Evangelismos Hospital
Hepatitis C Virus (HCV)
A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection
A Phase 3b, open-label, multicenter study to evaluate the efficacy and safety of glecaprevir/pibrentasvir for an 8- or 12-week treatment duration in participants with chronic hepatitis C virus (HCV) genotype (GT) 5 or 6…
- Trial name
- ENDURANCE-5 6 (NCT02966795)
- Testing
- Glecaprevir/Pibrentasvir
- Where
- 25 sites in United States, Australia and 7 more
- Volunteers
- 84 people
- Sponsor
- AbbVie
Pulmonary Disease, Chronic Obstructive
A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The Purpose of this study is to assess the efficacy and safety of two strengths of the FF/GW642444 Inhalation Powder in subjects with chronic obstructive pulmonary disease (COPD)
- Trial name
- NCT01053988
- Testing
- FF/GW642444 Inhalation Powder, FF Inhalation Powder, GW642444 Inhalation Powder
- Where
- 132 sites in United States, Chile and 8 more
- Volunteers
- 1,031 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.
This is a randomised, double-blind, double-dummy, multinational, multicentre, parallel group trial comparing tiotropium (18 mcg) inhalation capsule via HandiHaler and salmeterol (50 mcg) via MDI in patients with COPD.
- Trial name
- NCT00563381
- Testing
- Tiotropium bromide, Salmeterol
- Where
- 752 sites in Austria, Belgium and 23 more
- Volunteers
- 7,376 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Vahelva Respimat Regulatory Post-marketing Surveillance in Korean Patients With Chronic Obstructive Pulmonary Disease
To monitor the safety profile and effectiveness of Vahelva Respimat in Korean patients with COPD in a routine clinical practice setting
- Trial name
- NCT02864407
- Testing
- Vahelva® Respimat® (Tiotropium + Olodaterol fixed dose combination)
- Where
- South Korea
- Volunteers
- 3,223 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to measure the safety and tolerability of TD 4208, an investigational drug being developed to treat people with moderate to very severe COPD, compared to tiotropium.
- Trial name
- NCT02518139
- Testing
- TD-4208, Tiotropium
- Where
- United States
- Volunteers
- 1,060 people
- Sponsor
- Mylan Inc.
COPD
Acupuncture to Enhance for Pulmonary Rehab
The investigator is investigating if acupuncture may improve pulmonary function, exercise tolerance, stress and modulate the inflammatory effects of chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT04947800
- Testing
- Pulmonary rehabilitation program + EA Lung Mu-Shu+ St36, Pulmonary rehabilitation program + Lv7/Gb26
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Chronic Obstructive Pulmonary Disease
Exacerbation Study
This study compares indacaterol with tiotropium in terms of bronchodilation over 52 weeks
- Trial name
- INVIGORATE (NCT00845728)
- Testing
- Indacaterol 150 µg, Tiotropium
- Where
- 423 sites in Argentina, Australia and 38 more
- Volunteers
- 3,439 people
- Sponsor
- Novartis Pharmaceuticals
Central Serous Chorioretinopathy
Eplerenone for the Treatment of Central Serous Chorioretinopathy
To test the effect oral eplerenone versus placebo in patients with central serious chorioretinopathy .
- Trial name
- NCT01990677
- Testing
- 25mg Eplerenone
- Where
- 10 sites in United States
- Volunteers
- 108 people
- Sponsor
- Wills Eye
Pulmonary Disease, Chronic Obstructive
Influence Of Salmeterol Xinafoate/Fluticasone Propionate (50/500 µg BID) On The Course Of The Disease And Exacerbation Frequency In COPD Patients Gold Stage III And IV
This is a 12 month randomized, open-label, parallel-group study to obtain data on the frequency and variability of exacerbations in severe and very severe Chronic Obstructive Pulmonary Disease (COPD) patients (Global Initiative…
- Trial name
- NCT00527826
- Testing
- Salmeterol / Fluticasone (50/500 µg) BID fixed combination, Salmeterol / Fluticasone (50/500 µg) BID separate Inhalers
- Where
- 23 sites in Germany
- Volunteers
- 214 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
This study was conducted to provide detailed information on the efficacy of indacaterol in terms of its effect on spirometry assessed forced expiratory volume in 1 second (FEV1) over a 24 hour time period.
- Trial name
- NCT00622635
- Testing
- Indacaterol 300 μg, Salmeterol 50 μg
- Where
- 14 sites in United States, Belgium and 1 more
- Volunteers
- 68 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.